Novavax (NVAX) Downgraded by Zacks Investment Research to Sell
Novavax (NASDAQ:NVAX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
Other equities research analysts also recently issued research reports about the company. S&P Equity Research dropped their price objective on Novavax from $1.81 to $1.35 in a report on Wednesday, January 10th. B. Riley set a $10.00 price objective on Novavax and gave the company a “buy” rating in a report on Thursday, January 11th. Ladenburg Thalmann Financial Services upped their price objective on Novavax to $2.50 and gave the company a “buy” rating in a report on Thursday, January 11th. BidaskClub upgraded Novavax from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Finally, Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $3.68.
Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $8.35 million for the quarter, compared to the consensus estimate of $6.42 million. The company’s revenue was up 158.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) EPS. analysts predict that Novavax will post -0.62 EPS for the current year.
In related news, insider Stanley C. Erck acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the acquisition, the insider now owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
A number of large investors have recently bought and sold shares of NVAX. JPMorgan Chase & Co. grew its stake in Novavax by 40.1% in the second quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock valued at $5,976,000 after acquiring an additional 1,488,403 shares during the period. Nationwide Fund Advisors grew its stake in Novavax by 555.1% in the second quarter. Nationwide Fund Advisors now owns 1,024,020 shares of the biopharmaceutical company’s stock valued at $1,178,000 after acquiring an additional 867,700 shares during the period. GSA Capital Partners LLP grew its stake in Novavax by 38.7% in the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock valued at $1,944,000 after acquiring an additional 471,347 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Novavax by 39.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,153,971 shares of the biopharmaceutical company’s stock valued at $1,328,000 after acquiring an additional 326,415 shares during the period. Finally, Federated Investors Inc. PA acquired a new position in Novavax in the second quarter valued at about $232,000. 35.69% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/16/novavax-nvax-downgraded-by-zacks-investment-research-to-sell.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.